Safety and pharmacokinetics (PK) of T138067 (T67) administered as a weekly 3-hour infusion in subjects with hepatocellular carcinoma (HCC) in a phase 1 study. Journal of Clinical Oncology 2004 https://researcherprofiles.org/profile/79296664 A. P. Venook, E. K. Rowinsky, R. C. Donehower, T. Leung, L. C. Floren, M. Levy
